Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
Moodys
Harvard Business School
Dow

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Pegvisomant - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for pegvisomant and what is the scope of patent protection?

Pegvisomant is the generic ingredient in one branded drug marketed by Pharmacia And Upjohn and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Recent Clinical Trials for pegvisomant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 3
St. Michael's Hospital, TorontoPhase 3
NovartisPhase 4

See all pegvisomant clinical trials

US Patents and Regulatory Information for pegvisomant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-005 Jul 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for pegvisomant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003   Start Trial   Start Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-004 Jul 31, 2014   Start Trial   Start Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Merck
Dow
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.